First steps for Bionomics' anti-anxiety drug
Wednesday, 09 July, 2008
Bionomics [ASX: BNO] has completed GMP synthesis of its anxiety drug candidate BNC210, one of the first stages in its preparation for an IND application from the US FDA.
Pharmaceutical manufacturing contractors Sai Advantium completed the Good Manufacturing Practice (GMP) synthesis, and samples they have produced will be used in the final round of toxicological testing before human trials commence.
To successfully complete GMP synthesis all operational methodologies and procedures involved in creating the drug must be demonstrated to perform their intended function.
BNC210 is part of Bionomics' MultiCore technology platform. The company recently announced a major deal with Merck Serono to develop its potassium ion channel inhibitor kvl.3, and is in clinical trials for its vascular disruption agent BNC105.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
